Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Jenna D. Goldberg, Jeffrey R. Infante et al.|Blood Advances|2022Cited by 52
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).Alfred L. Garfall, María‐Victoria Mateos, Hareth Nahi et al.|Journal of Clinical Oncology|2020Cited by 42
Teclistamab: Mechanism of action, clinical, and translational scienceYue Guo, Danièle Ouellet, Natalia A. Quijano Cardé et al.|Clinical and Translational Science|2024Cited by 29
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Yusri Elsayed, Shun Xin Wang Lin et al.|Targeted Oncology|2022Cited by 21
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.Suzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Journal of Clinical Oncology|2021Cited by 5